Montecucco C, Baldi F, Fortina A, Tomassini G, Caporali R, Cherie-Ligniere E L, Fratino P
Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, Italy.
Clin Rheumatol. 1988 Sep;7(3):366-71. doi: 10.1007/BF02239194.
In 28 postmenopausal women with rheumatoid arthritis, serum osteocalcin (OC) concentration decreased from 5.2 +/- 1.9 ng/ml to 3.0 +/- 1.6 ng/ml after 6 months therapy with corticosteroids (p less than 0.005). No differences, however, were found in a control group of 13 patients treated for 6 months with nonsteroidal anti-inflammatory drugs. In those patients with serial OC measurements, changes in serum OC were already evident within the first month of therapy. This suggests that a suppressed osteoblast function may be detectable early during corticosteroid therapy in rheumatoid arthritis. Fifteen patients treated with prednisone (5-25 mg once daily, mean 12.33 mg/day) showed a more marked decrease in serum OC than 13 patients treated with equivalent doses of deflazacort (p less than 0.005). Prednisone therapy at doses higher than 10 mg/day resulted in a severe suppression of OC values in most cases. The effect of deflazacort was, however, mild in the majority of patients treated with doses of up to 30 mg/day.
在28名绝经后类风湿关节炎女性患者中,使用皮质类固醇治疗6个月后,血清骨钙素(OC)浓度从5.2±1.9 ng/ml降至3.0±1.6 ng/ml(p<0.005)。然而,在13名接受非甾体抗炎药治疗6个月的对照组患者中未发现差异。在那些进行了连续OC测量的患者中,血清OC的变化在治疗的第一个月内就已明显。这表明在类风湿关节炎患者接受皮质类固醇治疗的早期,可能就可检测到成骨细胞功能受到抑制。15名接受泼尼松治疗(每日一次,剂量5-25 mg,平均12.33 mg/天)的患者血清OC下降比13名接受等效剂量地夫可特治疗的患者更明显(p<0.005)。在大多数情况下,每天剂量高于10 mg的泼尼松治疗会导致OC值严重受抑制。然而,在大多数接受剂量高达30 mg/天的地夫可特治疗的患者中,其作用较为轻微。